MOG and myeloid sarcoma: With the discovery of antibodies targeting myelin oligodendrocyte glycoprotein (MOG) in AQP4 antibody-negative NMOSD, MOGAD is now recognized as a unique immunological entity that is distinct from both MS and NMOSD (4, 7).